Addex Therapeutics Ltd (ADXN) is a Healthcare · Biotechnology company listed on NASDAQ. Price $3.37 (+0.29%), Market cap $0.01B, 52-week low–high $5.66 ~ $10.95.
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia. The company also develops ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM); and GABAB PAM for the treatment pain, anxiety, addiction, cough, and overactive bladder. It has license and collaboration agreement with Jan
Financial statements, price targets, institutional (13F) holdings and related news for Addex Therapeutics Ltd are updated in real time on BlackAll Trade.
Addex Therapeutics Ltd trades at $3.37 (+0.29%). Real-time quotes and charts are available on BlackAll Trade.
Addex Therapeutics Ltd has a market cap of about $0.01B.
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupl